Last reviewed · How we verify

Nimenrix (GSK134612 vaccine) — Competitive Intelligence Brief

Nimenrix (GSK134612 vaccine) (Nimenrix (GSK134612 vaccine)) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Immunology.

phase 3 Immunology Biologic Live · refreshed every 30 min

Target snapshot

Nimenrix (GSK134612 vaccine) (Nimenrix (GSK134612 vaccine)) — GlaxoSmithKline. Nimenrix is a vaccine that induces immunity against meningococcal disease.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Nimenrix (GSK134612 vaccine) TARGET Nimenrix (GSK134612 vaccine) GlaxoSmithKline phase 3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Nimenrix (GSK134612 vaccine) — Competitive Intelligence Brief. https://druglandscape.com/ci/nimenrix-gsk134612-vaccine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: